Hyperlipoproteinemias Archives - MPR

Hyperlipoproteinemias

Higher Intensity Therapy With Simvastatin-Ezetimibe May Benefit Elderly Patients After ACS

According to the results of a secondary analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), treatment with simvastatin-ezetimibe appears to be beneficial for patients ≥75 years old with stabilized acute coronary syndrome (ACS), compared with simvastatin alone.   IMPROVE-IT was a randomized, double-blind, multicenter study that evaluated the outcomes and risks…

RNAi Therapy for Homozygous Familial Hypercholesterolemia Gets Orphan Drug Designation

The Food and Drug Administration (FDA) has granted Orphan Drug designation to ARO-ANG3 (Arrowhead Pharmaceuticals) for the treatment of homozygous familial hypercholesterolemia. ARO-ANG3 is a subcutaneously administered ribonucleic acid interference (RNAi) investigative treatment that works by reducing production of angiopoietin-like protein 3 (ANGPTL3), an inhibitor of lipoprotein lipase and endothelial lipase in the liver. The…

Ezallor capsule

FDA Approves Sprinkle Formulation of Rosuvastatin

The Food and Drug Administration (FDA) has approved a new sprinkle formulation of rosuvastatin, an HMG Co-A reductase inhibitor.  Ezallor Sprinkle (Sun Pharma) is indicated for the treatment of adult patients with: hypertriglyceridemia as an adjunct to diet; primary dysbetalipoproteinemia (Type III hyperlipoproteinemia) as an adjunct to diet; and homozygous familial hypercholesterolemia to reduce LDL-C,…

RNAi Therapeutic Gets Orphan Drug Status for Familial Chylomicronemia Syndrome

The Food and Drug Administration (FDA) has granted Orphan Drug designation to ARO-APOC3 (Arrowhead Pharmaceuticals), an investigational treatment for familial chylomicronemia syndrome (FCS). In FCS, mutations in lipoprotein lipase lead to an accumulation of chylomicrons in plasma resulting in severe hypertriglyceridemia. ARO-APOC3 is a subcutaneously administered RNAi therapeutic that targets apolipoprotein C-III (apoC-III), which according…